CDC Article-US Medical Eligibility Criteria for Contraceptive Use, 2010
CDC Article-US Medical Eligibility Criteria for Contraceptive Use, 2010
CDC Article-US Medical Eligibility Criteria for Contraceptive Use, 2010
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Vol. 59 / RR-4 Recommendations and Reports 47<br />
138. Demers R, Blais JA, Pretty H. Rheumatoid arthritis treated by norethynodrel<br />
associated with mestranol: clinical aspects and laboratory<br />
tests [in French]. Can Med Assoc J 1966;95:350–4.<br />
139. Drossaers-Bakker KW, Zwinderman AH, Van ZD, Breedveld FC,<br />
Hazes JM. Pregnancy and oral contraceptive use do not significantly<br />
influence outcome in long term rheumatoid arthritis. Ann Rheum Dis<br />
2002;61:405–8.<br />
140. Gilbert M, Rotstein J, Cunningham C, et al. Norethynodrel with mestranol<br />
in treatment of rheumatoid arthritis. JAMA 1964;190:235.<br />
141. Gill D. Rheumatic complaints of women using anti-ovulatory drugs.<br />
An evaluation. J Chronic Dis 1968;21:435–44.<br />
142. Hazes JM, Dijkmans BA, Vandenbroucke JP, Cats A. Oral contraceptive<br />
treatment <strong>for</strong> rheumatoid arthritis: an open study in 10 female<br />
patients. Br J Rheumatol 1989;28 Suppl 1:28–30.<br />
143. Ostensen M, Aune B, Husby G. Effect of pregnancy and hormonal<br />
changes on the activity of rheumatoid arthritis. Scand J Rheumatol<br />
1983;12:69–72.<br />
144. Vignos PJ, Dorfman RI. Effect of large doses of progesterone in rheumatoid<br />
arthritis. Am J Med Sci 1951;222:29–34.<br />
145. Bijlsma JW, Huber-Bruning O, Thijssen JH. Effect of oestrogen treatment<br />
on clinical and laboratory manifestations of rheumatoid arthritis.<br />
Ann Rheum Dis 1987;46:777–9.<br />
146. Cromer BA, Smith RD, Blair JM, Dwyer J, Brown RT. A prospective<br />
study of adolescents who choose among levonorgestrel implant<br />
(Norplant), medroxyprogesterone acetate (Depo-Provera), or the<br />
combined oral contraceptive pill as contraception. Pediatrics 1994;94<br />
:687–94.<br />
147. Gupta N, O’Brien R, Jacobsen LJ, et al. Mood changes in adolescents<br />
using depo-medroxyprogesterone acetate <strong>for</strong> contraception: a prospective<br />
study. Am J Obstet Gynecol 2001;14:71–6.<br />
148. Westoff C, Truman C. Depressive symptoms and Depo-Provera.<br />
Contraception 1998;57:237–40.<br />
149. Westoff C, Truman C, Kalmuss D, et al. Depressive symptoms and<br />
Norplant contraceptive implants. Contraception 1998;57:241–5.<br />
150. Smith JS. Cervical cancer and use of hormonal conraceptives: a systematic<br />
review. Lancet 2003;361:1159–67.<br />
151. Baeten JM, Nyange PM, Richardson BA, et al. Hormonal contraception<br />
and risk of sexually transmitted disease acquisition: results from<br />
a prospective study. Am J Obstet Gynecol 2001;185:380–5.<br />
152. Giuliano AR, Papenfuss M, Abrahamsen M, et al. Human papillomavirus<br />
infection at the United States–Mexico border: implications <strong>for</strong><br />
cervical cancer prevention and control. Cancer Epidemiol Biomarkers<br />
Prev 2001;10:1129–36.<br />
153. Jacobson DL, Peralta L, Farmer M, et al. Relationship of hormonal<br />
contraception and cervical ectopy as measured by computerized<br />
planimetry to chlamydial infection in adolescents. Sex Transm Dis<br />
2000;27:313–9.<br />
154. Lavreys L, Chohan B, Ashley R, et al. Human herpesvirus 8: seroprevalence<br />
and correlates in prostitutes in Mombasa, Kenya. J Infect Dis<br />
2003;187:359–63.<br />
155. Morrison CS, Bright P, Wong EL, et al. Hormonal contraceptive use,<br />
cervical ectopy, and the acquisition of cervical infections. Sex Transm<br />
Dis 2004;31:561–7.<br />
156. Moscicki AB, Hills N, Shiboski S, et al. Risks <strong>for</strong> incident human<br />
papillomavirus infection and low-grade squamous intraepithelial lesion<br />
development in young females. JAMA 2001;285:2995–3002.<br />
157. Nso<strong>for</strong> BI, Bello CS, Ekwempu CC. Sexually transmitted disease<br />
among women attending a family planning clinic in Zaria, Nigeria.<br />
Int J Gynaecol Obstet 1989;28:365–7.<br />
158. Ruijs GJ, Kauer FM, van Gijssel PM, Schirm J, Schroder FP. Direct<br />
immunofluorescence <strong>for</strong> Chlamydia trachomatis on urogenital smears<br />
<strong>for</strong> epidemiological purposes. Eur J Obstet Gyneco Reprod Biol<br />
1988;27:289–97.<br />
159. Aklilu M, Messele T, Tsegaye A, et al. Factors associated with HIV-1<br />
infection among sex workers of Addis Ababa, Ethiopia. AIDS<br />
2001;15:87–96.<br />
160. Allen S, Serufilira A, Gruber V, et al. Pregnancy and contraception use<br />
among urban Rwandan women after HIV testing and counseling. Am<br />
J Public Health 1993;83:705–10.<br />
161. Baeten JM, Benki S, Chohan V, et al. Hormonal contraceptive use,<br />
herpes simplex virus infection, and risk of HIV-1 acquisition among<br />
Kenyan women. AIDS 2007;21:1771–7.<br />
162. Bulterys M, Chao A, Habimana P, et al. Incident HIV-1 infection in a<br />
cohort of young women in Butare, Rwanda. AIDS 1994;8:1585–91.<br />
163. Carael M, Van de Perre PH, Lepage PH, et al. Human immunodeficiency<br />
virus transmission among heterosexual couples in Central Africa.<br />
AIDS 1988;2:201–5.<br />
164. Cohen CR, Duerr A, Pruithithada N, et al. Bacterial vaginosis and<br />
HIV seroprevalence among female commercial sex workers in Chiang<br />
Mai, Thailand. AIDS 1995;9:1093–7.<br />
165. Criniti A, Mwachari CW, Meier AS, et al. Association of hormonal<br />
contraception and HIV-seroprevalence in Nairobi, Kenya. AIDS<br />
2003;17:2667–9.<br />
166. Kapiga SH, Shao JF, Lwihula GK, Hunter DJ. Risk factors <strong>for</strong> HIV<br />
infection among women in Dar-es-Salaam, Tanzania. J Acquir Immune<br />
Defic Syndr 1994;7:301–9.<br />
167. Kapiga SH, Lyamuya EF, Lwihula GK, Hunter DJ. The incidence of<br />
HIV infection among women using family planning methods in Dar<br />
es Salaam, Tanzania. AIDS 1998;12:75–84.<br />
168. Kiddugavu M, Makumbi F, Wawer MJ, et al. Hormonal contraceptive<br />
use and HIV-1 infection in a population-based cohort in Rakai,<br />
Uganda. AIDS 2003;17:233–40.<br />
169. Kilmarx PH, Limpakarnjanarat K, Mastro TD, et al. HIV-1 seroconversion<br />
in a prospective study of female sex workers in northern<br />
Thailand: continued high incidence among brothel-based women.<br />
AIDS 1998;12:1889–98.<br />
170. Kleinschmidt I, Rees H, Delany S, et al. Injectable progestin contraceptive<br />
use and risk of HIV infection in a South African family planning<br />
cohort. Contraception 2007;75:461–7.<br />
171. Lavreys L, Chohan V, Overbaugh J, et al. Hormonal contraception and<br />
risk of cervical infections among HIV-1-seropositive Kenyan women.<br />
AIDS 2004;18:2179–84.<br />
172. Limpakarnjanarat K, Mastro TD, Saisorn S, et al. HIV-1 and other<br />
sexually transmitted infections in a cohort of female sex workers in<br />
Chiang Rai, Thailand. Sex Transm Infect 1999;75:30–5.<br />
173. Martin HL, Jr., Nyange PM, Richardson BA, et al. Hormonal contraception,<br />
sexually transmitted diseases, and risk of heterosexual<br />
transmission of human immunodeficiency virus type 1. J Infect Dis<br />
1998;178:1053–9.<br />
174. Mati JK, Hunter DJ, Maggwa BN, Tukei PM. <strong>Contraceptive</strong> use and<br />
the risk of HIV infection in Nairobi, Kenya. Int J Gynaecol Obstet<br />
1995;48:61–7.<br />
175. Morrison CS, Richardson BA, Mmiro F, et al. Hormonal contraception<br />
and the risk of HIV acquisition. AIDS 2007;21:85–95.<br />
176. Myer L, Denny L, Wright TC, Kuhn L. Prospective study of hormonal<br />
contraception and women’s risk of HIV infection in South Africa. Int<br />
J Epidemiol 2007;36:166–74.